Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022784 · ClinicalTrials.gov registry record
Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,798
- Enrollment target
NCT05022784: Completed study, sponsored by Boehringer Ingelheim.
NCT05022784 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,798 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05022784 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,798 participants
- Enrollment target
Study Summary
This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: * Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. * Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.
Primary Outcome
The number of IPF patients per adherence trajectories to nintedanib is presented. The first claim for nintedanib was used for defining the initiation date. For each 30-day month (12 months) following the nintedanib initiation date, the Proportions of Days Covered (PDC) were calculated as the sum of days with supply divided by 30, the monthly nintedanib proportion of days covered was then calculated. The twelve 30-days PDC values were used as outcomes in the Group-based trajectory model (GBTM), t
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,798 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2021-12-30 |
What the finished NCT05022784 record still lists
NCT05022784 is an observational study that tracks outcomes without assigning an intervention. Its 1,798 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT05022784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05022784 about?
NCT05022784 is a clinical study titled "Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients". This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: * Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. * Understanding characteristics of patients withi...
What is the current status of trial NCT05022784?
This trial is currently completed. The enrollment target is 1,798 participants. The study started on 2021-08-23. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT05022784?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT05022784?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI